Who raises this issue and when it is raised during the consultation depends on many factors, which may include the patient’s pre-test understanding of BRCA1/BRCA2 mutation risks, family history and response to ovarian cancer treatment. The gene discussed is BRCA1; the disease is ovarian cancer.